Patents by Inventor Vladimir Tolmachev

Vladimir Tolmachev has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240124533
    Abstract: A HER2-binding polypeptide is provided, comprising the amino acid sequence SEQ ID NO: 1. Also provided is a radiolabeled polypeptide consisting of a radiochelate of the HER2-binding polypeptide and a radionuclide. Also provided are methods and uses employing the polypeptide in therapeutic, diagnostic and prognostic applications, e.g. relating to cancers characterized by overexpression of HER2.
    Type: Application
    Filed: February 15, 2022
    Publication date: April 18, 2024
    Inventors: Fredrik FREJD, Vladimir TOLMACHEV
  • Publication number: 20230165982
    Abstract: There is provided an imaging agent for use in a method of visualization of HER2 expression in a human patient, said method comprising administering the imaging agent to the patient in a dose of 400-700 ?g and subsequently a scanning of the patient to visualize HER2 expression, wherein the imaging agent is a conjugate comprising a radionuclide and a HER2-binding protein (HBP) of a certain amino acid sequence. Further there is provided a unit dose comprising the imaging agent in an amount of 400-700 ?g.
    Type: Application
    Filed: April 30, 2020
    Publication date: June 1, 2023
    Inventors: Sophia Hober, Javad Garousi, Vladimir Tolmachev, Bragina Olga, Sarah Lindbo, Vladimir Chernov
  • Publication number: 20230107890
    Abstract: There is provided a therapeutic conjugate comprising a fusion protein and a cytotoxic radionuclide, which cytotoxic radionuclide is bound to the fusion protein. The fusion protein comprises a certain HER2-binding region (HBR), a certain albumin-binding region (ABR) and a spacer region.
    Type: Application
    Filed: March 9, 2021
    Publication date: April 6, 2023
    Inventors: Sophia Hober, Emma von Witting, Javad Garousi, Vladimir Tolmachev
  • Patent number: 8883120
    Abstract: HER2 binding polypeptides comprising the amino acid sequence EX1 RNAYWEIA LLPNLTNQQK RAFIRKLYDD PSQSSELLX2E AKKLNDSQ wherein X1 in position 2 is M, I or L, and X2 in position 39 is S or C (SEQ ID NO:1) are disclosed. Moreover, such peptides comprising a chelating environment are disclosed. Also radiolabeled polypeptides formed by the peptides comprising a chelating environment and radionuclides are disclosed. Furthermore, methods of in vivo imaging of the body of a mammalian subject having or suspected of having a cancer characterized by overexpression of HER2 comprising administration of such a radiolabeled polypeptide followed by obtainment of an image of the body using a medical imaging instrument and also methods of treating such cancer are disclosed. Furthermore, the use of such a radiolabeled polypeptide in diagnosis and treatment of cancer characterized by overexpression of HER2.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: November 11, 2014
    Assignee: Affibody AB
    Inventors: Lars Abrahmsén, Nina Herne, Joachim Feldwisch, Christofer Lendel, Vladimir Tolmachev
  • Publication number: 20130280164
    Abstract: HER2 binding polypeptides comprising the amino acid sequence EX1 RNAYWEIA LLPNLTNQQK RAFIRKLYDD PSQSSELLX2E AKKLNDSQ wherein X1 in position 2 is M, I or L, and X2 in position 39 is S or C (SEQ ID NO:1) are disclosed. Moreover, such peptides comprising a chelating environment are disclosed. Also radiolabeled polypeptides formed by the peptides comprising a chelating environment and radionuclides are disclosed. Furthermore, methods of in vivo imaging of the body of a mammalian subject having or suspected of having a cancer characterized by overexpression of HER2 comprising administration of such a radiolabeled polypeptide followed by obtainment of an image of the body using a medical imaging instrument and also methods of treating such cancer are disclosed. Furthermore, the use of such a radiolabeled polypeptide in diagnosis and treatment of cancer characterized by overexpression of HER2.
    Type: Application
    Filed: June 27, 2013
    Publication date: October 24, 2013
    Inventors: Lars Abrahmsén, Nina Herne, Joachim Feldwisch, Christofer Lendel, Vladimir Tolmachev
  • Patent number: 8501909
    Abstract: HER2 binding polypeptides comprising the amino acid sequence EX1 RNAYWEIA LLPNLTNQQK RAFIRKLYDD PSQSSELLX2E AKKLNDSQ wherein X1 in position 2 is M, I or L, and X2 in position 39 is S or C (SEQ ID NO: 1) are disclosed. Moreover, such peptides comprising a chelating environment are disclosed. Also radiolabeled polypeptides formed by the peptides comprising a chelating environment and radionuclides are disclosed. Furthermore, methods of in vivo imaging of the body of a mammalian subject having or suspected of having a cancer characterized by overexpression of HER2 comprising administration of such a radiolabeled polypeptide followed by obtainment of an image of the body using a medical imaging instrument and also methods of treating such cancer are disclosed. Furthermore, the use of such a radiolabeled polypeptide in diagnosis and treatment of cancer characterized by overexpression of HER2.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: August 6, 2013
    Assignee: Affibody AB
    Inventors: Lars Abrahmsén, Nina Herne, Joachim Feldwisch, Christofer Lendel, Vladimir Tolmachev
  • Publication number: 20110117012
    Abstract: The Invention relates to conjugates of formula (III) or (IIIa), or a salt thereof, their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes.
    Type: Application
    Filed: January 21, 2011
    Publication date: May 19, 2011
    Applicant: GE HEALTHCARE LIMITED
    Inventors: VLADIMIR TOLMACHEV, BENGT LANGSTROM, ASA LILJEGREN SUNDBERG, IRINA VELIKYAN
  • Publication number: 20060188441
    Abstract: Methods for labeling synthesis of radiolabeled gallium complex by microwave activation are provided. The resultant gallium-isotope labeled compounds are useful as radiopharmaceuticals, especially for use in Positron Emission Tomography (PET). A method for imaging EGFR overexpression in tumors using PET is also provided.
    Type: Application
    Filed: February 21, 2006
    Publication date: August 24, 2006
    Inventors: Vladimir Tolmachev, Bengt Langstrom, Asa Sundberg, Irina Velikyan